4.6 Article

Effects of Brain Parcellation on the Characterization of Topological Deterioration in Alzheimer's Disease

期刊

FRONTIERS IN AGING NEUROSCIENCE
卷 11, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fnagi.2019.00113

关键词

Alzheimer's disease; mild cognitive impairment; high angular resolution diffusion imaging; structural connectivity network; fiber tracking

资金

  1. Natural Science Foundation of Zhejiang Province [LY17E070007]
  2. National Natural Science Foundation of China [51207038]
  3. China Scholarship Council
  4. University of Houston
  5. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  6. National Institute on Aging
  7. National Institute of Biomedical Imaging and Bioengineering
  8. AbbVie
  9. Alzheimer's Association
  10. Alzheimer's Drug Discovery Foundation
  11. Araclon Biotech
  12. BioClinica, Inc.
  13. Biogen
  14. Bristol-Myers Squibb Company
  15. CereSpir, Inc.
  16. Cogstate
  17. Eisai Inc.
  18. Elan Pharmaceuticals, Inc.
  19. Eli Lilly and Company
  20. EuroImmun
  21. F. Hoffmann-La Roche Ltd
  22. Genentech, Inc.
  23. Fujirebio
  24. GE Healthcare
  25. IXICO Ltd.
  26. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  27. Johnson & Johnson Pharmaceutical Research & Development LLC.
  28. Lumosity
  29. Lundbeck
  30. Merck Co., Inc.
  31. Meso Scale Diagnostics, LLC.
  32. NeuroRx Research
  33. Neurotrack Technologies
  34. Novartis Pharmaceuticals Corporation
  35. Pfizer Inc.
  36. Piramal Imaging
  37. Servier
  38. Takeda Pharmaceutical Company
  39. Transition Therapeutics
  40. Canadian Institutes of Health Research
  41. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]

向作者/读者索取更多资源

Alzheimer's disease (AD) causes the progressive deterioration of neural connections, disrupting structural connectivity (SC) networks within the brain. Graph-based analyses of SC networks have shown that topological properties can reveal the course of AD propagation. Different whole-brain parcellation schemes have been developed to define the nodes of these SC networks, although it remains unclear which scheme can best describe the AD-related deterioration of SC networks. In this study, four whole-brain parcellation schemes with different numbers of parcels were used to define SC network nodes. SC networks were constructed based on high angular resolution diffusion imaging (HARDI) tractography for a mixed cohort that includes 20 normal controls (NC), 20 early mild cognitive impairment (EMCI), 20 late mild cognitive impairment (LMCI), and 20 AD patients, from the Alzheimer's Disease Neuroimaging Initiative. Parcellation schemes investigated in this study include the OASIS-TRT-20 (62 regions), AAL (116 regions), HCP-MMP (180 regions), and Gordon-rsfMRl (333 regions), which have all been widely used for the construction of brain structural or functional connectivity networks. Topological characteristics of the SC networks, including the network strength, global efficiency, clustering coefficient, rich-club, characteristic path length, k-core, rich-club coefficient, and modularity, were fully investigated at the network level. Statistical analyses were performed on these metrics using Kruskal-Wallis tests to examine the group differences that were apparent at different stages of AD progression. Results suggest that the HCP-MMP scheme is the most robust and sensitive to AD progression, while the OASIS-TRT-20 scheme is sensitive to group differences in network strength, global efficiency, k-core, and rich-club coefficient at k-levels from 18 and 39. With the exception of the rich-club and modularity coefficients, ML could not significantly identify group differences on other topological metrics. Further, the Gordon-rsfMRl atlas only significantly differentiates the groups on network strength, characteristic path length, k-core, and rich-club coefficient. Results show that the topological examination of SC networks with different parcellation schemes can provide important complementary AD-related information and thus contribute to a more accurate and earlier diagnosis of AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据